Keyuan Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 64.69 million yuan, up 51.6% year on year. Operating revenue was 331 million yuan, up 45.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 55.91 million yuan, up 55.9% year on year. Net operating cash flow was 42.26 million yuan, up 65.3% year on year. Earnings per share were 0.5974 yuan. In the second quarter, operating revenue was 170 million yuan, up 45.9% year on year, and net profit attributable to the parent was 34.62 million yuan, up 76.6% year on year. As of the end of the second quarter, total assets were 1.911 billion yuan, up 13.2% from the end of the previous year, and net assets attributable to the parent were 1.43 billion yuan, up 5.5% from the end of the previous year. The company focuses on the research, development, production and sales of chemical active pharmaceutical ingredients and their formulation products, and has made strategic arrangements in areas such as glucose-lowering and weight-loss therapies, anti-aging biology and brain-computer interfaces.
Shandong Keyuan Pharmaceutical Co. Ltd. AFirst-half net profit up 51.6% and revenue up 45.5%.
